Immuno-histochemical staining confirmed the nuclear expression of RBMY only in HCC tumor tissues (Fig. 2E).The positive rate of RBMY transcripts was 36% (16/44) in HBV-related HCC, 40% (4/10) in HCV-related HCC, 20% (1/5) in HBV/HCV-related HCC, and 29% (2/7) non-viral related HCC. Here, RBMY1A1 is linked to hepatocellular carcinoma.